ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "IL-23"

  • Abstract Number: 1944 • 2017 ACR/ARHP Annual Meeting

    A Dual Role for IL-23 Receptor Signaling in Normal Bone Remodeling Versus Inflammation-Mediated Bone Damage during Arthritis

    Wida Razawy1, Marijke Koedam2, Patrick Asmawidjaja3, Anne-Marie Otten-Mus4, Bram van der Eerden2 and Erik Lubberts3, 1Rheumatology and Immunology, Erasmus MC, Rotterdam, Netherlands, 2Internal Medicine, Erasmus MC, Rotterdam, Netherlands, 3Rheumatology and Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, 4Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands

    Background/Purpose: The interleukin (IL)-23/IL-17A immune pathway is critical for the development of autoimmune arthritis. Systemic exposure of IL-23 induced chronic arthritis, increased osteoclast differentiation and…
  • Abstract Number: 645 • 2017 ACR/ARHP Annual Meeting

    An Oral Tyk2 Inhibitor Effectively Suppresses the Development of Murine Th17 Cells In Vivo and Prevents Joint Damage in Experimental Ankylosing Spondylitis

    Eric Gracey1,2, Melissa Lim2, Zoya Qaiyum1, Yuriy Baglaenko1,2, Wenyan Miao3, Craig Masse3, William Westlin3 and Robert D Inman1,4, 1Department of Immunology, University of Toronto, Toronto, ON, Canada, 2Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 3Nimbus Therapeutics, Cambridge, MA, 4Toronto Western Hospital, University Health Network, toronto, ON, Canada

    Background/Purpose: Th17 cells play an important role in the pathogenesis of ankylosing spondylitis (AS). Tyk2, a member of the Janus Kinase (JAK) family of signaling…
  • Abstract Number: 659 • 2017 ACR/ARHP Annual Meeting

    IL-17 Producing T Cells and Its Dichotomy: A Mixed Response of the Innate and Acquired Immune System in Psoriatic Arthritis

    Siba P. Raychaudhuri1 and Smriti K. Raychaudhuri2, 1Rheumatology Section, Sacramento Veterans Affairs Medical Center, Sacramento, CA, 2Rheumatology/Immunology, VA Sacramento Medical Center, Davis, CA

     Background/Purpose:     Source of IL-17 in human has been mainly attributed to ab T cells, more specifically to the Th17 cells. However, some reports suggest…
  • Abstract Number: 11L • 2016 ACR/ARHP Annual Meeting

    BMS-986165 Is a Highly Potent and Selective Allosteric Inhibitor of Tyk2, Blocks IL-12, IL-23 and Type I Interferon Signaling and Provides for Robust Efficacy in Preclinical Models of Systemic Lupus Erythematosus and Inflammatory Bowel Disease

    Kathleen Gillooly1, Yifan Zhang1, Xiaoxia Yang1, Adriana Zupa-Fernandez1, Lihong Cheng1, Joann Strnad1, Mark Cunningham2, Elizabeth Heimrich1, Xiadi Zhou1, Jing Chen3, Charu Chaudhry3, Sha Li3, Kim McIntyre1, Julie Carman4, Ryan Moslin5, Stephen Wrobleski5, David Weinstein5 and James Burke1, 1Immunosciences Discovery Biology, Bristol-Myers Squibb, Princeton, NJ, 2Bristol-Myers Squibb, Princeton, NJ, 3Leads Discovery & Optimization, Bristol-Myers Squibb, Princeton, NJ, 4Discovery Translational Sciences Group, Bristol-Myers Squibb, Princeton, NJ, 5Immunosciences Discovery Chemistry, Bristol-Myers Squibb, Princeton, NJ

    Background/Purpose: Tyk2 mediates signaling downstream of the receptors for IL-12, IL-23 and Type I interferons, all key drivers of autoimmune disorders such as SLE. BMS-986165,…
  • Abstract Number: 960 • 2016 ACR/ARHP Annual Meeting

    Ultrasonographic Improvement of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated with Ustekinumab for Chronic Plaque Psoriasis: A 52-Week, Prospective, Open Label, Controlled Cohort Study

    Laura Savage1, Mark Goodfield2, Elizabeth M.A. Hensor3, Paul Emery3 and Dennis McGonagle4, 1NIHR Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, 2Department of Dermatology, Leeds Centre for Dermatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 3NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Subclinical enthesopathy is recognised in up to 50% of psoriasis patients and is thought to precede inflammatory PsA. It is not known if effective…
  • Abstract Number: 1678 • 2016 ACR/ARHP Annual Meeting

    JAK STAT Kinase Cascade Regulates the IL-23/IL-17 Cytokine Axis in Psoriatic Arthritis

    Siba P. Raychaudhuri1 and Smriti K. Raychaudhuri2, 1Davis, CA, 2Rheumatology/Immunology, VA Sacramento Medical Center, Davis, CA

    Background/Purpose: Aberrant activation of IL-23/IL-17 cytokine axis is a dominant pathology in the psoriatic disease. IL-23 regulates expansion/maintenance/functional maturation of Th17 cells. Th17 cells along…
  • Abstract Number: 1752 • 2016 ACR/ARHP Annual Meeting

    IL-23 Promotes the Generation of DNT Cells and Shifts the Balance Between IL-2 and IL-17 Production in Murine and Human SLE

    Hong Dai1,2, Fan He1,2, George C. Tsokos1,2 and Vasileios C. Kyttaris1,2, 1Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA, 2Harvard Medical School, Boston, MA

    Background/Purpose: MRL/lpr mice develop a chronic inflammatory disease characterized by accumulation of CD4-CD8-B220+T cells mimicking human lupus; IL-23 driven IL-17 producing cell contribute to lupus…
  • Abstract Number: 2694 • 2016 ACR/ARHP Annual Meeting

    Treatment of ZAP-70 Mutant SKG Mice with Anti-IL-23 Antibody Alters Fecal Microbiota Composition and Prevents Outgrowth of Bacteria Associated with Susceptibility to Spondyloarthritis and Ileitis

    Linda Rehaume1, Nicholas Matigian1, Alicia Kang1, Olga Zbarskaya1, Kristine Kikly2, Nancy Lachner3, Joshua Daly3, Philip Hugenholtz3, Mark Morrison1, Kim-Anh Lê Cao4 and Ranjeny Thomas1, 1Translational Research Institute, The University of Queensland Diamantina Institute, Brisbane, Australia, 2Biotechnology Discovery Research, Eli Lilly and Co, Indianapolis, IN, 3The University of Queensland, Australian Centre for Ecogenomics, Brisbane, Australia, 4Translational Research Instiute, The University of Queensland Diamantina Institute, Brisbane, Australia

    Background/Purpose: Identification of disease-associated or protective bacteria may elucidate new biomarkers or probiotic supplements for people suffering from spondyloarthritis (SpA), or for people at-risk of…
  • Abstract Number: 2711 • 2016 ACR/ARHP Annual Meeting

    Tissue-Resident IL-23 Responsive Innate T Cells in Mice Comprise Tcrαβ+ and TCRγδ+ Subsets with Overlapping Function

    Katia Urso, Imtiyaz Hossain and Joerg Ermann, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Multiple lines of evidence suggest a critical role for the IL-23/IL-17A axis in spondyloarthritis. In susceptible inbred strains, hydrodynamic injection of IL-23 minicircles into…
  • Abstract Number: 2715 • 2016 ACR/ARHP Annual Meeting

    Genetic Variants in TNF, TNFRSF1A, and IL23R Are Associated with Risk of Ankylosing Spondylitis

    Jacob Sode1,2,3, Ulla Vogel4, Steffen Bank5, Paal Skytt Andersen6, Merete Lund Hetland7, Henning Locht2, Niels H. H. Heegaard8 and Vibeke Andersen9, 1Department of Autoimmunology and Biomarkers, Statens Serum Institut, Copenhagen, Denmark, 2Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark, 3Department of Rheumatology, Skåne University Hospital, Lund, Sweden, 4National Research Centre for the Working Environment, Copenhagen, Denmark, 5Institute of Human Genetics, University of Aarhus, Aarhus, Denmark, 6Microbiology & Infection Control, Statens Serum Institut, Copenhagen S, Denmark, 7DANBIO Registry and Departments of Rheumatology, Rigshospitalet (Glostrup and Blegdamsvej), University of Copenhagen, Glostrup, Denmark, 8Department of Autoimmunology & Biomarkers, Statens Serum Institut, Copenhagen, Denmark, 9Odense University Hospital, OPEN (Odense Patient data Explorative Network), Odense, Denmark

    Background/Purpose: The objective of this study was to evaluate single nucleotide polymorphisms (SNPs) involved in TNFα signaling, NF-κB activation, interferon-γ signaling, or pattern recognition receptor…
  • Abstract Number: 2144 • 2015 ACR/ARHP Annual Meeting

    Efficacy and Safety of Different Dose Regimens of a Selective IL-23p19 Inhibitor (BI 655066) Compared with Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis with and without Psoriatic Arthritis

    Kim Papp1, Alan Menter2, Howard Sofen3, Stephen Tyring4, Jean-Philippe Lacour5, Beate Berner6, Nathan Bennett7, Stella Aslanyan7, Mary Flack7 and Paul Scholl7, 1Probity Clinical Research, Waterloo, ON, Canada, 2Baylor Research Institute, Dallas, TX, 3Dermatology Research Associates, Los Angeles, CA, 4Center for Clinical Studies, Houston, TX, 5Dermatology Department, Hôpital de L’Archet, Nice, France, 6Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, 7Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT

     Background/Purpose: IL-23 is essential for the differentiation and maintenance of Th17 cells in psoriasis and psoriatic arthritis (PsA). We assessed the efficacy and safety of…
  • Abstract Number: 2809 • 2015 ACR/ARHP Annual Meeting

    Increased Frequencies of IL-23R Positive T Cells and IL-22 and IL-17 Producing MAIT Cells in the Peripheral Blood of Patients with Ankylosing Spondylitis: Preliminary Results.   

    Eric Toussirot1, Caroline Laheurte2, Béatrice Gaugler3 and Philippe Saas4, 1Service de Rhumatologie, CHU J Minjoz, Besancon, France, 2Etablissement Français du Sang/ Université de Franche Comté / CBT506 / CHRU, INSERM UMR1098 / Plateforme Biomonitoring, Besançon, France, 3EFS Bourgogne Franche Comté, INSERM UMR1098 / Etablissement Français du Sang / Université de Franche Comté, Besançon, France, 4Etablisement Français du Sang ; Université de Franche Comté, INSERM UMR1098, Besançon, France

    Background/Purpose: Ankylosing spondylitis (AS) is the prototypic and most common form of spondyloarthritis (SpA). It was recently suggested that IL-23 could play a pivotal role…
  • Abstract Number: 2819 • 2015 ACR/ARHP Annual Meeting

    Rorc Antagonism Inhibits IL-23-Dependent Aberrant Bone Formation in Vivo

    Mark Panzenbeck1, Kathleen Hoyt1, Donald Souza2, Gregg Davis1, Elizabeth Glynn1, Thomas Wieckowski1, Michael Turner1, Robert Hughes1, Dustin Smith1, Christian Harcken1, Gerald Nabozny3 and Mark Labadia4, 1Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, 2Immunology & Inflammation, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, 3Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, 4Immunology, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT

    Background/Purpose: RORγt is a nuclear hormone receptor expressed in Th17 cells and distinct subsets of lymphoid cells, including innate lymphoid cells (ILC), and γδ T-cells.…
  • Abstract Number: 2822 • 2015 ACR/ARHP Annual Meeting

    Increased Peripheral Blood CCR6+/IL-23R+ Gamma Delta T Cells Are Associated with High Disease Activity in Patients with Axial Spondyloarthritis

    Elizabeth Mainolfi1, Susan M. Goodman2, Shawn Anderson3, Jon Hill4, Thakker Paresh5, Meera Ramanujam6, Rivka Friedlander7, Elli Kim7, Dalit Ashany8, Ed Purdue9, Christine Averill9, Michael Nevid9, Allison Shaber9, Lisa Mandl10, Steven R. Goldring11, Gerald Nabozny1 and VP Bykerk2, 1Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, 2Rheumatology, Hospital for Special Surgery, New York, NY, 3Immunology, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, 4Scientific Knowledge Discovery, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, 5Transl. Medicine & Clin. Pharmacology, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, 6Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, 7Department of Medicine, Rheumatology Division, Hospital for Special Surgery, New York, NY, 8Rheumatic Disease, Hospital for Special Surgery, New York, NY, 9Osteolysis Research Laboratory, Hospital for Special Surgery, New York, NY, 10Department of Rheumatology, Hospital for Special Surgery, New York, NY, 11Hospital for Special Surgery, New York, NY

    Background/Purpose:  The IL-23 axis and Th17 type immunity has been implicated in the pathogenesis  of Ankylosing Spondylitis (AS) and an enrichment of gamma delta (gd)…
  • Abstract Number: 2830 • 2015 ACR/ARHP Annual Meeting

    Synovial Fluid T Cells of Patients with Reactive Arthritis  and Undifferentiated Spondyloarthropathy Respond to Salmonella Typhimurium Outer Membrane Protein a and  Induces IL17 and IL23 Production By  Synovial Fluid Mononuclear Cells

    Ramnath Misra1, Smriti Chaurasia1, Ajit K Shashny2 and Amita Aggarwal3,4, 1Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 2Central Institute of Medicinal and Aromatic Plants, Scientist, Lucknow, India, 3Clinical Immunology, Additional Professor Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Lucknow, India, 4Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

    Background/Purpose: We have previously shown that synovial fluid mononuclear cells (SFMCs) of patients with Reactive arthritis (ReA) and undifferentiated Spondyloarthropathy (uSpA) proliferated to low molecular…
  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology